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Abstract
Background: Increased rates for failure in leishmaniasis antimony treatment have been recently recognized worldwide.
Although several risk factors have been identified there is no clinical score to predict antimony therapy failure of cutaneous
leishmaniasis.
Methods: A case control study was conducted in Peru from 2001 to 2004. 171 patients were treated with pentavalent
antimony and followed up to at least 6 months to determine cure or failure. Only patients with ulcerative cutaneous
leishmaniasis (N=87) were considered for data analysis. Epidemiological, demographical, clinical and laboratory data were
analyzed to identify risk factors for treatment failure. Two prognostic scores for antimonial treatment failure were tested for
sensitivity and specificity to predict antimony therapy failure by comparison with treatment outcome.
Results: Among 87 antimony-treated patients, 18 (21%) failed the treatment and 69 (79%) were cured. A novel risk factor for
treatment failure was identified: presence of concomitant distant lesions. Patients presenting concomitant-distant lesions
showed a 30.5-fold increase in the risk of treatment failure compared to other patients. The best prognostic score for
antimonial treatment failure showed a sensitivity of 77.78% and specificity of 95.52% to predict antimony therapy failure.
Conclusions: A prognostic score including a novel risk factor was able to predict antimonial treatment failure in cutaneous
leishmaniasis with high specificity and sensitivity. This prognostic score presents practical advantages as it relies on clinical
and epidemiological characteristics, easily obtained by physicians or health workers, and makes it a promising clinical tool
that needs to be validated before their use for developing countries.
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Introduction
Leishmaniasis is caused by protozoan parasites of the genus
Leishmania sp. There is an estimated 2 million new cases and almost
70 000 attributable deaths worldwide every year [1]. Leishman-
iasis includes a cluster of diseases with widely diverse clinical
manifestations. These include three major groups of clinical
disorders: visceral leishmaniasis (VL), cutaneous leishmaniasis
(CL), and mucocutaneous leishmaniasis (MCL) [2–4]. New world
cutaneous Leishmaniasis (also known as American Tegumentary
Leishmaniasis) is endemic in the Andean region affecting the most
deprived socioeconomic groups.
Pentavalent antimonials (SbV) have been the first line drugs for
leishmaniasis treatment for more than 50 years. Studies
conducted in Latin America have reported rates of antimony
failure ranging from 7% up to 39% [5–7], raising a serious
concern on health policy makers. Several factors like the parasite
species [8,9], the duration of the period living in the endemic
area [10], the duration of the presence of skin lesions before the
start of treatment, and the presence of multiple cutaneous lesions,
were found to be significantly associated with SbV therapy failure
[9,10].
The use of clinical scores as predictive tools is being more
frequently used in several conditions. It provides a valuable tool for
clinical management, orienting physicians to establish the most
appropriate treatments [11]. Given the considerably high level of
antimonial resistance [12] and the need to develop strategies to
improve the treatment of patients [12,13], a clinical score to
predict SbV treatment failure would have an important impact on
the control efforts for CL leishmaniasis.
www.plosntds.org 1 June 2012 | Volume 6 | Issue 6 | e1656This study evaluates potential risk factors and disease severity
parameters for SbV treatment failure of ulcerative cutaneous
leishmaniasis. A predictive score for antimonial treatment failure
(PSATF) is generated in a nested case-control study conducted in
Peru.
Materials and Methods
Patients
We performed a nested case-control study from a prospective
cohort that took place between November 2001 and December
2004 at the Leishmaniasis Clinic of the Instituto de Medicina
Tropical ‘‘Alexander von Humboldt,’’ Universidad Peruana
Cayetano Heredia, in Lima, Peru. The clinic serves patients from
nearly all areas of endemicity in the country.
Subjects from both sexes and all ages with a first episode of
parasitologically confirmed CL by direct Giemsa stained smear or
positive culture were recruited. Patients with only ulcerative lesions
and with a first diagnosis of CL without mucosal, disseminated or
diffuse lesions, who received at least 20 doses of antimonials, and
who were followed for at least 6 months after starting SbV
treatment were included.
The patient’s population included in this study was a sub-cohort
of a larger sample previously reported [8]. Written, informed
consent was obtained from all patients. In case of children their
parents or guardians gave consent. Research protocols complied
with national and international ethics policies. The human
experimentation guidelines of the Institute of Tropical Medicine
Antwerp were followed. Ethics clearance was obtained from the
ethical committees of the Universidad Peruana Cayetano Heredia
and the Institute of Tropical Medicine Antwerp, Belgium. Clinical
and epidemiological data for each patient were available from a
previous study [8].
Chemotherapy
Patients received treatment on site, with standard supervised
daily administration of generic sodium stibogluconate (SSG) from
Colombia (Viteco SA, lots: 10700, 10800, 20600, 20700 and
30600) or India (Albert David Ltd, lot: 3P12001) following
Ministry of Health (MHO) of Peru guidelines (20 mg Sb5+/kg/
day), for 20 days by intravenous or intramuscular injection.
Quality control for SbV concentration in all batches was
performed by the International Dispensary Association (Amster-
dam, The Netherlands). Follow-up visits were scheduled for 1, 2,
3, 6, and 12 months after treatment ended. Patients with treatment
failure received either a repeat course of antimonials with or
without topical imiquimod (Aldara; 3 M Pharmaceuticals) or
intravenous amphotericin B (amphotericin B deoxycholate;
Bristol-Myers Squibb).
Treatment outcome
After completion of the therapy, patients were schedule at 1, 2,
3, 6 and 12 month to evaluate the progression of the disease. On
each visit the patient was clinically classified as (1) cure, if complete
wound healing, with epithelization and absence of any sign of
activity or inflammation or (2) failure, if increased inflammation
around the initial lesion, with or without epithelization, clinical
reactivation of a healed lesion, or presence of new lesion(s) or a
satellite lesion around the initial one was evidenced. Pending was
record in patients that evidence lesion in progress to closure.
Treatment failure was considered if lesion received clinical
classification of failure after 3 months of follow up. Patients
clinically classified as cure continued the follow up scheme in order
to monitor relapse.
Potential risk factors for treatment failure
Information available for patients included age, sex, body mass
index (BMI), main occupation, geographical region where disease
was acquired, and disease severity parameters. Main occupation
was classified as low or high risk for exposure to insect bites. High-
risk occupations included agriculture, mining, and logging. Lesion
description included number, type, location, and lymph node
compromise. Typing of the leishmania species isolated from
patients was performed as previously described [8].
Parameters that reflect the severity of the ulcerative lesions were
measured. These included time of the disease and lesion size,
which was calculated as (transversal diameter/2)6(sagital diame-
ter/2)63.14. On patients with multiple ulcerated lesions, the total
area was calculated considering areas of the three largest lesions.
Time of disease was defined as the time period since the
recognition of the first lesion until the start of treatment.
Another parameter considered was the presentation of ‘‘con-
comitant-distant’’ lesions at the time of enrollment. This param-
eter was defined as the appearance of more than one lesion in
different segments of the body (head, arms, trunks and legs) within
15 days. Cutaneous lesions that appeared in the same body
segment were considered satellital lesions but not ‘‘concomitant-
distant’’.
In all cases age was expressed in years, time of disease in days,
and the total area of lesion in cm
2. Gender was considered 0 if
female and 1 for male. Genotype L. braziliensis was considered ‘‘1’’
if leishmania type is L. braziliensis, otherwise it was considered ‘‘0’’.
The covariate low/high risk activity is considered ‘‘1’’ in case of a
high-risk occupation otherwise it was considered ‘‘0’’. The
concomitant-distant ulcers category was ‘‘1’’ if it was present,
otherwise it was considered ‘‘0’’.
Statistical analysis
Categorical variables were described by frequencies and
proportions. Continuous variables were described by means,
medians and standard deviation. Categorical variables were
compared by using chi-squared test. t-test and ANOVA were
used to compare normally distributed variables while U Mann-
Author Summary
The manuscript is relevant because of the finding of a new
risk factor for chemotherapy failure and the development
of a prognosis score for cutaneous leishmaniasis. The
proportion of patients that have multiple lesions in
American Tegumentary Leishmaniasis (ATL) is consider-
able. Publications and our experience permit to estimate
that they represent around 20% of the affected population
from the Amazon basin with cutaneous lesions. In
addition, about 1/3 of them would correspond to the
concomitant distant lesions category, the novel risk factor
identified with a very high odds ratio (20–30) associated.
Such numbers merit study of concomitant distant ulcers
category on its own, not only because of clinical
management implications, but also to search for factors
that are contributing to chemotherapy failure. Finally, the
simple equation proposed in the manuscript can be easily
adapted to smart phone technologies. Similar prognosis
equations are scarce for other pathologies and do not exist
for Cutaneous Leishmaniasis at all. The simplicity of this
tool should be followed by subsequent epidemiologic
studies in other ATL endemic regions.
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distributed variables.
The probability of treatment failure was modeled in a multiple
logistic regression. Potential clinical risk factors and severity
indicators were tested as predictors after adjusting for potential
confounders. Interactions and second order effects were tested.
Multi-dimensional outliers were assessed with the test of Hadi
[14]. Covariates that were significant in the univariate analysis and
were not over-correlated with other covariates (correlation
coefficient less than 0.75) were included in the multiple regression
analysis. Nested models were compared with the likelihood ratio
test. The best sensitivity and specificity of the PSATF was
estimated by maximizing the Youden’s index, J=sensitivity+spe-
cificity21 [15].
A clinical tool to predict antimony treatment failure was created
using the best multiple logistic regression model. The probability
of treatment failure was calculated as:
Probability of failure~1

1ze-L 
Where L is the linear predictor of the best multiple logistic model
(a0+a1 X1+a2 X2+….+an Xn, where Xi are the significant
covariates included in the best multiple model, and ai are the
regression coefficients. All the statistical analyses were conducted
with a 5% significance level using the software Stata 10.
Results
A total of 171 patients received a diagnosis of leishmaniasis. In
all these patients the parasite was isolated and typed during the
study period. Of these patients, 87 met the eligibility criteria for
ulcerative lesions and were included in the analysis. Eighteen
patients (20.7%) failed the treatment and 69 (79.3%) cured. The
age distribution ranged from 0.3–85 yr with a mean of 29 yr.
Thirty patients (34.5%) were female and 57 (65.5%) were male.
Fifty-two patients (59.8%) presented single lesions. The number of
lesions in patients classified as multiple lesions ranges from 2 to 7.
Among patients with multiples lesions, 10 (23%) showed ‘‘con-
comitant-distant’’ lesions.
A total of 84 patients did not meet eligibility criteria and were
excluded from the analysis: 14 had previously received treatment
for leishmaniasis, 18 presented mucosal involvement, 10 did not
complete the first round of SbV treatment, 14 were followed-up
for only 6 months, and 28 presented non-ulcerative lesions
(nodule, plaque, mixed).
Descriptive statistics were compared between patients that
cured and failed to treatment (Table 1). In the univariate analysis,
patients who failed treatment were younger (mean=16.2 years)
than patients that cured (mean=32.4 years) (P,0.001). Treatment
failure was significantly associated with the type of work activity.
People living in areas with a high rate of insect bites presented
lower risk of chemotherapy failure (P,0.001). Time of disease and
the size of induration, although border line significant, were
included in the logistic regression analysis.
Among the clinical parameters that define the severity of the
disease, the total area of lesions and the presence of ‘‘concomitant-
distant’’ lesions, were significantly associated with treatment
failure. Total area of lesions in patients that cured was greater
than in patients that failed treatment (2.7 cm
2 vs 1.26 cm
2,U -
Man-Whitney test, P=0.007). Fifty percent of people with
concomitant-distant lesions failed to antimony chemotherapy
whereas only 17% failed among the patients that presented either
single or multiple non-concomitant-distant lesions.
The unadjusted odds ratios estimated from the univariate
analysis for treatment failures are shown in Table 2. Covariates
significantly associated with treatment outcome were: Age,
occupation, parasite species induration size, the natural logarithm
of the total area of lesion, and the presentation of concomitant-
distant lesions. The presence of concomitant-distant lesions
showed a remarkably highly significant association in the
univariate model (OR=4.92, P=0.023). The number of lesions
was not significantly associated with treatment failure. The
logarithmic transformation of the total area of lesion evidenced
a significant association (OR=0.50, P=0.006).
The best multiple logistic model to explain treatment failure
included six covariates significantly associated with treatment
outcome (Table 2). The regression coefficients of the linear
predictor of the best multiple logistic model were used to calculate
the PSATF-1 (PS1=1/(1+e
2L
1), where L1=6.61720.12
(age)+3.24 (L. braziliensis)20.027 (Time of disease)20.64 (log
total area lesion +1)+3.41 (Concomitant-distant)22.65 (low/high
risk activity)). Noteworthy, the presence of concomitant-distant
lesions and the type of Leishmania species were strongly associated
with treatment failure (odds ratios of 30.5 and 25.7 respectively).
Table 1. Epidemiologial, clinical and laboratory
characteristics of patients with ulcerative cutaneous
leishmaniasis stratified by cure or failure condition with
pentavalent antimonial treatment in Peru.
Variable Cure Failed P-value
Gender 0.318
Male 22 (73.3%) 8 (23.67%)
Female 47 (82.46%) 10 (17.54%)
Age (mean+2SD) 32.36+219.72 16.17+212.81 0.001
Activity 0.001
Low risk 30 (65.22%) 16 (34.78%)
High risk 38 (95%) 2 (5%)
Geographic location 0.90
Central and northern coast 27 (81.82%) 6 (18.18%)
High amazone 31 (79.49%) 8 (20.51%)
Southern Andes 2 (66.67%) 1 (33.3%)
Low Amazone 9 (75%) 3 (25%)
Duration of disease
* (days) 77.5 (45–114) 60 (31–86) 0.068
Total area of lesion(s)
* (cm2) 2.71 (1.32–3.93) 1.27 (0.34–2.07) 0.007
Total number lesions
* 1 (1–2) 2 (1–2) 0.95
Skin test diameter (mm)
Mean+2SD
9.12+22.92 7.41+21.37 0.053
Concomitant-distant lesions 0.015
No 64 (83.12%) 13 (16.88%)
Yes 5 (50%) 5 (50%)
Genotype 0.123
L. guyanensis 22 (91.67%) 2 (8.33%)
L. braziliensis 17 (68%) 8 (32%)
L. peruviana 30 (78.95%) 8 (21.05%)
Mean and standard deviation (SD) or frequencies were compared between
cured and failed cases to antimony chemotherapy patients when normally
distributed covariates were involved.
Median and (25
th–75
th) percentiles (inter-quartile range) were compared in
variables with non normal distribution.
doi:10.1371/journal.pntd.0001656.t001
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6 to 30, showed a statistical power from 0.64 to 0.99 respectively.
The best model explained 54% of the variability of treatment
failure. The total area under the Receiver Operating Curve was
0.93 (Figure 1). The best sensitivity and specificity that maximized
the Youden’s index were 77.78 and 92.52 respectively, for a PS1
cutoff of 0.4 (if PS1.0.4 failure is prognosticated, otherwise it is
expected a cure). Different sets of sensitivity and specificity of PS1
were tabulated for different cutoff values (Table 3).
In addition we evaluated a score to model the chemotherapy
failure without considering the leishmania specie (PSATF-2 (PS2)).
This multivariate model included four significant variables and was
able to explain 38.7% of the chemotherapy failure (Figure 1).
Concomitant-distant lesions remained the most important predictor
of chemotherapy failure (OR=6.27, although significance was
0.054).The optimal sensitivity and specificity of PS2 weredetermined
by maximizing the Youden index and reached 66.67% and 92.54%
respectively, which corresponded to a PS2 cutoff of 0.4.
Table 2. Logistic regression models to predict antimony treatment failure of ulcerative cutaneous leishmaniasis.
Factor
Univariate analysis
a
OR (95% CI) P-value
Multiple-variable analysis
1
b OR (95% CI) P-value
Multiple-variable analysis
2
c OR (95% CI) P-value
Age 0.94 (0.89–0.97) 0.003 0.88 (0.81–0.97) 0.010 0.92 (0.88–0.98) 0.008
Duration of disease 0.99 (0.97–1.00) 0.138 0.97 (0.95–0.99) 0.025 0.97(0.94–0.99) 0.02
high-risk/low risk Activity 0.098 (0.02–0.46) 0.003 0.07 (0.009–0.54) 0.011 0.12(0.02–0.75) 0.02
Number of lesion(s) 0.93 (0.32–2.7) 0.896
Total area of lesion(s)* 0.499 (0.31–0.82) 0.006 0.53 (0.27–1.04) 0.065
Concomitant-distant lesion(s)
No 1 1 1
Yes 4.92 (1.24–19.48) 0.023 30.5 (1.67–558.56) 0.021 6.27(0.96–40.7) 0.054
Leishmania species
L guyanensis 11
L braziliensis 5.17 (0.97–27.60) 0.054 25.7 (2.34–282.30)** 0.008
L peruviana 2.93 (0.56–15.19) 0.200 1
aOdds ratio and its 95% confidence interval of the simple logistic regression in the univariate analysis.
bOdds ratio and its 95% confidence interval of the multiple logistic regression for the Prognostic Score 1. R
2=0.54; 85 patients in the model.
cOdds ratio and its 95% confidence interval of the multiple logistic regression for the Prognostic Score 2 (without inclusion of the Leishmania species). R
2=0.38; 85
patients in the model.
*This variable was log-transformed before the analysis.
**Odds ratio obtained after pooling L. guyanensis and L. peruviana and comparing against L. brasiliensis.
doi:10.1371/journal.pntd.0001656.t002
Figure 1. Receiver Operating Curve for the Prognostic Score 1 (PS1) and Prognostic Score 2 (PS2) of antimony chemotherapy
treatment failure.
doi:10.1371/journal.pntd.0001656.g001
Score for Treatment Failure in Leishmaniasis
www.plosntds.org 4 June 2012 | Volume 6 | Issue 6 | e1656The regression coefficients of the linear predictor of the reduced
multiple logistic model (Table 4), were used to calculate the
PSATF-2 (PS2=1/(1+e
2L
2), where L2=2.8420.073
(age)20.028 (Time of disease)+1.83 (Concomitant-distant)22.06
(low/high risk activity)). A free Excel-based electronic calculator of
PSATF-1 and PSATF-2 (Calculator S1) is available at the online
supplementary material or upon request to the authors.
Discussion
We report here for the first time a score for prognosis of
antimonial therapeutic failure in ulcerative CL patients treated
with SSG. This prognostic score PSATF (PS1) includes a newly
identified risk factor that was highly associated with the risk of
treatment failure: the appearance of concomitant-distant lesions.
The proposed prognostic score could be used as a clinical
prediction tool able to be adjusted (PS2 instead of PS1) according
to the level of the technical capacity available on site.
The two most important factors included in the PSATF, were
the appearance of concomitant-distant lesions and the species
of Leishmania associated to infection. The appearance of
concomitant-distant lesions compared to patients with unique or
non-concomitant-distant multiple lesions appear as a promising
important clinical finding to be considered during treatment of
leishmaniasis. Although a relatively small number of cases give
support to this finding, the high OR (30.5) is statistically significant
(p=0.023). However, a larger cohort study will be required to
confirm this finding. Confirming the findings in other studies
[8,10], infection with L. braziliensis also accounts as an important
risk factor for treatment failure (OR=25.7).
A limitation is that concomitant-distant lesions may not be
identified at a very early stage of the disease. However, considering
that in developing countries, patients seek medical attention lately,
this limitation would not prevent the appropriate use of the
prognostic score in the majority of situations.
As showed in Table 1 Previous works by our group and others
[10,16] showed the relationship between the area of lesion and the
chemotherapy failure. This suggests that contrary to what is a
common concept of treatment of leishmaniasis, early treatment
and in consequence a smaller lesion size seems to be a risk for
chemotherapy failure.
The frequency of SbV treatment failure estimated in this study
was as high as reported in other sites [8–10]. About 20% of
patients fail to SbV treatment in a first treatment scheme.
Therefore it is important to predict failure with a reasonable
sensitivity and specificity. The PSATF proposed could provide
different combinations of sensitivities and specificities, according to
specific necessities. The PSATF cut off of 0.4 has privileged the
specificity over sensitivity to optimize the safety and rational use of
chemotherapy with SbVs. The optimal values of sensitivity and
specificity indicate that 78% of patients who failed treatment were
correctly predicted while 92.5% of patients who cured were
classified as such. In this way a larger proportion of patients will be
correctly treated with the drug that is provided free of costs by the
ministry of health while avoiding the use of second line drugs that
have adverse side effects and are more expensive [17,18]. Similar
approaches to determine prognostic scores of treatment failure
have been proposed for other diseases such as tuberculosis [19].
Clinical scores were also developed to predict fatal outcome in
patients with visceral leishmaniasis [20,21].
Our proposed PSATF includes two different models depending
on the availability of genotyping of Leishmania species. Given that
in some settings genotyping is not possible to perform, the use of
model PS2 that does not require genotyping appears to be an
alternative to improve the management of this disease in those
places. It is important to highlight that the sensitivity and
specificity are not largely compromised when the species of
leishmania is excluded.
The appearance of concomitant-distant lesions was highly
associated with the risk of treatment failure in contrast to the
Table 3. Sensitivity and specificity to predict antimony
treatment failure for the different cutoffs of the linear scores
for the Prognostic Scores 1 and 2.
Prognostic Score 1 Prognostic Score 2
Probability cutoff Sensitivity Specificity Sensitivity Specificity
0.6 55.56 98.51 44.44 98.51
0.5 72.22 95.52 61.11 95.52
0.4 77.78 95.52 66.67 92.54
0.37 77.78 94.03 66.67 89.55
0.35 77.78 94.03 66.67 85.07
0.3 77.78 91.04 66.67 83.58
0.29 77.78 91.04 66.67 82.09
0.27 83.33 88.06 66.67 77.61
0.25 83.33 86.57 77.78 76.12
0.23 83.33 85.07 77.78 76.12
0.2 83.33 76.12 77.78 74.63
Prognostic Score 1. Linear score model based on the multiple logistic regression
that included the six significant covariates described in Table 2.
Prognostic Score 2. Linear score model based on the multiple logistic regression
that included the four significant covariates described in Table 2.
doi:10.1371/journal.pntd.0001656.t003
Table 4. Regression coefficients of the logistic models for chemotherapy failure.
Variable Prognostic Score 1 P-value Prognostic Score 2 P-value
Age 20.12 0.01 2.073 0.07
Duration of disease 20.03 0.02 20.03 0.02
Total area of lesio ´n(s) 20.64 0.06
Concomitant-distant lesion(s) 3.41 0.02 1.83 0.05
Low/high risk activity 22.65 0.01 22.06 0.02
L. brasilienzis 3.25 0.01
Constant term 6.62 ,0.01 2.84 0.02
doi:10.1371/journal.pntd.0001656.t004
Score for Treatment Failure in Leishmaniasis
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total number of lesions has been previously suggested to be a risk
factor for SbV treatment failure [9,10], but in these studies,
concomitant-distant lesions were not distinguished.
Cutaneous leishmaniasis is characterized by lesion(s) that
progress from an erythema to the typical ulcerative form in a
range of 2–24 weeks [22]. All the patients included in the study
were clinically classified as ulcerative cutaneous leishmaniasis and
the number of lesions range from 1 to 7. Concomitant distant
lesions do not seem to be the typical clinical form of disseminated
leishmaniasis since it is characterized by the presence of numerous
ulcerative and papular lesions.
Given its remarkable importance, it is likely that the appearance
of concomitant-distant lesions correspond to a different biological
phenomenon that needs to be further studied. A possibility is that
these lesions could be a consequence of an intrinsic immune failure
that favors metastasis [23], or a consequence of multiple infected
sand-fly bites on different parts of the body [24]. However, in both
cases it might indicate a decreased capability of the immune
system to undergo a cell-mediated immunity against leishmania
parasites.
The PSATF here presented has practical advantages because it
depends on observable clinical and epidemiological features, easily
obtained by physicians or health workers. With the increased use
of portable computational systems, the prognostic score PSATF
could be easily used by physicians in tablet PCs and smartphones.
Prospective clinical studies should probe its value as prognostic
tool.
Supporting Information
Calculator S1 Excel-based calculator for PS1 and PS2.
(XLS)
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